The Importance of Measuring Executive Function When Studying the Effects of Cognition-Enhancing Agents
TO THE EDITOR:
In their comprehensive systematic review, Raina and colleagues (1) noncontroversially conclude that the effect sizes for cholinesterase inhibition in Alzheimer disease typically are small and that translation of these effects into patients' quality of life remains problematic. Perhaps even more can be concluded from the literature. If we accept that the average small effect size represents a distribution of effects, it is reasonable to ask why some people seem to do well in response to treatment and others do not. There are 3 possible answers.
First, a dose response can be demonstrated at the group level, such that patients who can tolerate the highest doses commonly demonstrate effect sizes in the moderate range …
This 100-word excerpt has been provided in the absence of an abstract.
Most Read
